Indication and Important Safety Information скачать в хорошем качестве

Indication and Important Safety Information

This content is intended for US healthcare professionals only. Please see Full Prescribing Information, including Boxed WARNING, at https://abbv.ie/ElaherePI. Watch to learn more about the Indication and Important Safety Information for ELAHERE® (mirvetuximab soravtansine-gynx). INDICATION ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test. SELECT IMPORTANT SAFETY INFORMATION WARNING: OCULAR TOXICITY ● ELAHERE can cause severe ocular toxicities, including visual impairment, keratopathy, dry eye, photophobia, eye pain, and uveitis. ● Conduct an ophthalmic exam including visual acuity and slit lamp exam prior to initiation of ELAHERE, every other cycle for the first 8 cycles, and as clinically indicated. ● Administer prophylactic artificial tears and ophthalmic topical steroids. ● Withhold ELAHERE for ocular toxicities until improvement and resume at the same or reduced dose. ● Discontinue ELAHERE for Grade 4 ocular toxicities. © 2024 AbbVie. All rights reserved. US-MIRV-2400171 ELAHERE and its design are trademarks of ImmunoGen, Inc., an AbbVie company.